CN110780070B - Plasma protein molecule for detecting cancer chemotherapy sensitivity, application and kit - Google Patents
Plasma protein molecule for detecting cancer chemotherapy sensitivity, application and kit Download PDFInfo
- Publication number
- CN110780070B CN110780070B CN201910924077.0A CN201910924077A CN110780070B CN 110780070 B CN110780070 B CN 110780070B CN 201910924077 A CN201910924077 A CN 201910924077A CN 110780070 B CN110780070 B CN 110780070B
- Authority
- CN
- China
- Prior art keywords
- chemotherapy
- plasma protein
- human plasma
- sensitivity
- pancreatic cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 45
- 102000004506 Blood Proteins Human genes 0.000 title claims abstract description 44
- 108010017384 Blood Proteins Proteins 0.000 title claims abstract description 44
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 32
- 230000035945 sensitivity Effects 0.000 title claims abstract description 28
- 201000011510 cancer Diseases 0.000 title claims abstract description 19
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 30
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 30
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 30
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 30
- 230000004044 response Effects 0.000 claims abstract description 23
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims abstract description 21
- 102100028953 Gelsolin Human genes 0.000 claims abstract description 21
- 101000806793 Homo sapiens Apolipoprotein A-IV Proteins 0.000 claims abstract description 21
- 101001059150 Homo sapiens Gelsolin Proteins 0.000 claims abstract description 21
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 claims abstract description 21
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102100024521 Ficolin-2 Human genes 0.000 claims description 15
- 101001052753 Homo sapiens Ficolin-2 Proteins 0.000 claims description 15
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 claims description 11
- 238000007637 random forest analysis Methods 0.000 claims description 10
- 238000012795 verification Methods 0.000 claims description 6
- 102100020985 Immunoglobulin mu heavy chain Human genes 0.000 claims description 5
- 101710099741 Immunoglobulin mu heavy chain Proteins 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 238000012549 training Methods 0.000 claims description 4
- 238000004422 calculation algorithm Methods 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 238000009104 chemotherapy regimen Methods 0.000 claims 3
- 230000035572 chemosensitivity Effects 0.000 claims 2
- 230000005929 chemotherapeutic response Effects 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 8
- 239000000439 tumor marker Substances 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000004458 analytical method Methods 0.000 description 5
- 239000012474 protein marker Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000003066 decision tree Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 description 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/004—Artificial life, i.e. computing arrangements simulating life
- G06N3/006—Artificial life, i.e. computing arrangements simulating life based on simulated virtual individual or collective life forms, e.g. social simulations or particle swarm optimisation [PSO]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Artificial Intelligence (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Computational Linguistics (AREA)
- Data Mining & Analysis (AREA)
- Evolutionary Computation (AREA)
- Computing Systems (AREA)
- General Engineering & Computer Science (AREA)
- Mathematical Physics (AREA)
- Software Systems (AREA)
Abstract
The invention discloses a plasma protein molecule for detecting cancer chemotherapy sensitivity, application and a kit. A plasma protein molecule for detecting cancer chemotherapy sensitivity comprises at least one of human plasma proteins GSN, APOA4, IGHG1, immunologlobulin mu heavy chain and FCN 2. The research of the invention finds that the concentration of the human plasma protein has obvious difference in pancreatic cancer patients with different chemotherapy responses, and the area under the ROC curve for predicting the pancreatic cancer chemotherapy response can reach 0.5550-0.7275 when the human plasma protein is used as a tumor marker alone; the area under the ROC curve of the five human plasma protein concentration combinations used as tumor markers for predicting the pancreatic cancer chemotherapy response in combination with the age of a patient can reach 0.915, and the human plasma protein concentration combinations can be used as tumor markers for predicting the tumor chemotherapy sensitivity, so that the effective screening of chemotherapy-sensitive people is realized, and the clinical benefit is greatly improved.
Description
Technical Field
The invention relates to the technical field of biotechnology detection, in particular to a plasma protein molecule for detecting cancer chemotherapy sensitivity, application and a kit.
Background
Tumors are one of the important diseases threatening human life and health. Pancreatic cancer is the most malignant tumor, and is called the king of cancer. The occult onset of the cancer is such that many patients often lose the chance of surgical operation during diagnosis, and the poor response rate of chemotherapy greatly limits the prognosis of pancreatic cancer patients.
With the research of multiple researches in recent years, some chemotherapy schemes such as FOLFIRINOX, nano albumin paclitaxel and gemcitabine are gradually separated out, and become a main chemotherapy strategy for treating pancreatic cancer. Unfortunately, however, these regimens remain very limited in their effectiveness in the pancreatic cancer population. Therefore, the search for effective tumor markers helps to accurately identify chemotherapy-benefited people, and has important significance for improving the prognosis of pancreatic cancer patients. CA19-9 is one of the most commonly used tumor markers in clinic, and has good sensitivity and specificity for pancreatic cancer diagnosis. Based on the expression pattern of CA19-9, it was found that the FOLFIRINOX regimen resulted in a higher objective sustained release rate (ORR, 44.0% vs. 22.9%) for patients with a more than 20% decrease in CA 19-9. However, CA19-9 is not expressed in all pancreatic cancer patients, nor is this strategy able to predict patient response prior to chemotherapy. To solve this problem, some studies have searched for markers of tumor circulating DNA and serum proteins, and found that biomarkers such as ctdna (kras), CEA, and sCD40L can predict the sensitivity of chemotherapeutic drugs to some extent. However, the sensitivity and specificity of prediction of these biomarkers, either alone or in combination, have been difficult to meet clinical needs. Therefore, the development of a new tumor marker has good application prospect in predicting drug sensitivity before chemotherapy.
With the development and maturation of technology, mass spectrometry-based proteomics strategies are gradually expanding in clinical detection and basic research. The technical characteristics of high flux, high sensitivity and high accuracy bring great convenience to the biomedical field, and the large-scale screening of the biomarkers becomes possible. Therefore, the strategy of utilizing omics big data is used for screening new markers and constructing a prediction model of multiple markers, or the accuracy of chemotherapy prediction can be improved to a new level.
Disclosure of Invention
The research of the invention finds that the plasma protein concentrations of free proteins GSN, APOA4, IGHG1, Immunoglobulin mu heavy chain (IgM heavy chain) and FCN2 extracted from human peripheral blood show significant difference in pancreatic cancer patients with different chemotherapy responses, and further analysis can find that the high expression of serum GSN, APOA4, Immunoglobulin mu heavy chain and FCN2 and the low expression of IGHG1 are related to the sensitivity of tumors to the FOLFIRINOX scheme. The protein molecule is used for constructing a pancreatic cancer chemotherapy response prediction model, the area under the working characteristic (ROC) curve of a subject can reach 0.88, and the area under the ROC curve of pancreatic cancer chemotherapy response predicted by combining the age of a patient can reach 0.915. Therefore, the prediction model constructed by combining the plasma protein marker molecules with the clinical information of the patient can be used as a tumor marker for predicting tumor chemotherapy response, and further helps to clinically screen chemotherapy-sensitive people.
A plasma protein molecule for detecting cancer chemotherapy sensitivity comprises at least one of human plasma proteins GSN, APOA4, IGHG1, immunologlobulin mu heavy chain and FCN 2.
Preferably, the plasma protein molecule comprises one of the following protein combinations: GAI, GAF, GAM, GIF, GIM, GFM, AIF, AFM, IFM, AIM, wherein G: GSN, A: APOA4, I: IGHG1, M: immunoglobulin mu heavy chain, F: FCN 2.
More preferably, the plasma protein molecules comprise human plasma proteins GSN, APOA4, IGHG1, immunologlulin mu heavy chain and FCN 2. The result is more accurate when the five human plasma proteins are combined together.
The invention also provides application of the plasma protein molecule in serving as a target for detecting cancer chemotherapy sensitivity. The application, the cancer type is pancreatic cancer. The chemotherapy is FOLFIRINOX.
The application comprises the steps of detecting the concentrations of human plasma proteins GSN, APOA4, IGHG1, immunoglulin mu heavy chain and FCN2 in plasma, and inputting the 5 kinds of human plasma protein concentration data into a pre-generated random forest model to carry out prediction and evaluation on the chemotherapy response of a patient.
The construction method of the pre-generated random forest model comprises the following steps:
taking concentration data of human plasma proteins GSN, APOA4, IGHG1, Immunoglobulin mu heavy chain and FCN2 in the plasma of patients with known FOLFIRINOX regimen sensitivity and resistance,
setting the seed number as 2019, randomly grouping according to the ratio of 2: 1 to construct a training set and a verification set, and importing concentration matrixes of 5 proteins, treatment response conditions and corresponding clinical information: and (3) constructing a model by using a random forest algorithm, repeating the operation for 100 times to obtain an ROC working curve for average prediction of the model, setting the number of trees to be 1000, setting the minimum observed data number of the peripheral nodes to be 1: 5, and fitting by using a anger function to obtain a final model.
The present invention also provides a kit for detecting cancer chemotherapy sensitivity, comprising:
(1) reagents for extracting proteins from plasma;
(2) the reagent is used for detecting the concentrations of human plasma proteins GSN, APOA4, IGHG1, immunologlobulin muheavy chain and FCN 2.
The research of the invention finds that the concentrations of human plasma proteins GSN, APOA4, IGHG1, immunolobulin mu heavy chain and FCN2 are obviously different in pancreatic cancer patients with different chemotherapy responses, and the area under the ROC curve for predicting the pancreatic cancer chemotherapy response can reach 0.5550-0.7275 when the human plasma proteins GSN, APOA4, IGHG1, immunolobulin mu heavy chain and FCN2 are used as tumor markers independently; the area under the ROC curve for predicting the pancreatic cancer chemotherapy response by using the five human plasma protein concentration combinations as tumor markers in combination with the patient age can reach 0.915. Therefore, based on the combination of plasma protein molecules GSN, APOA4, IGHG1, immunolobulin muheavy chain and FCN2 (including any combination of the five proteins and any combination of all parts of the five proteins) and clinical information of a patient, the tumor marker for predicting tumor chemotherapy sensitivity can be used as a tumor marker for assisting with a random forest model constructed in the early stage, so that the effective screening of chemotherapy-sensitive people is realized, and the clinical benefit is greatly improved.
Drawings
FIG. 1 is a graph of plasma protein concentrations versus results for chemotherapy resistant and sensitive pancreatic cancer patients.
FIG. 2 is a diagram of the decision tree results of one of the models extracted during model building in example 3.
FIG. 3 is a graph of the results of sensitivity and specificity analysis of plasma protein combinations in the prediction of pancreatic cancer chemotherapy response.
FIG. 4 is a graph of the results of a sensitivity and specificity analysis of the single protein marker model in the prediction of pancreatic cancer chemotherapy response.
FIG. 5 is a graph of the results of sensitivity and specificity analysis in response prediction of pancreatic cancer chemotherapy using a traditional three-protein marker combination model based on binary Logistic regression analysis.
Detailed Description
Sample source: plasma samples from pancreatic cancer patients were obtained from the first hospital affiliated with the university of Zhejiang medical college.
Ethical examination and approval: ethical review by ethical review committee of scientific research in first hospital affiliated to Zhejiang university medical college, lot number: (2019) research review quick review No. (622).
Example 1
Plasma proteins were extracted from peripheral blood samples. The method comprises the following steps:
peripheral blood was collected from human using an anticoagulation blood collection tube, centrifuged (3000g, 4 ℃ C., 20 minutes) to remove blood cells, and the supernatant was frozen at-80 ℃ in a refrigerator. During detection, the supernatant is taken out and frozen, and then the supernatant is thawed at 4 ℃. Centrifugation (10000g, 60 min) was carried out to remove large cell debris and the like. Mu.l of the supernatant was added to 200. mu.l of a protein extract (purchased from Biognosys, product number of kit: Ki-3013) and mixed well, followed by standing at 4 ℃ for 5 minutes. After centrifugation (14000g, 4 ℃, 10 minutes), the supernatant was removed to obtain a plasma protein sample.
Example 2
Plasma protein samples were quantitated using the method steps of a protein quantitation kit (purchased from Thermo Fisher, product number: 23225). The protein was subjected to enzymatic hydrolysis using protease (purchased from Biognosys, Inc., kit product No. Ki-3013) to obtain a peptide fragment which was used for processing. And according to the quantitative result, the same amount of nuclide-labeled standard peptide fragment (purchased from Biognosys company, product number: Ki-3019) is added to the polypeptide sample with the same content to prepare the peptide fragment sample for being installed on a computer.
Example 3
The sample in example 2 was subjected to mass spectrometric detection to obtain a quantitative result of the target protein. And calculating the plasma concentration of the target protein according to the absolute quantitative result and the volume of the upper computer sample, and introducing the obtained concentration into a random forest model constructed in the early stage so as to predict the chemotherapy response condition of the patient.
The test relates to 40 plasma samples of pancreatic cancer chemotherapy patients, wherein the FOLFIRINOX scheme is sensitive to 25 patients and the drug-resistant patients are 15 patients, and the results show that the levels of GSN, APOA4, IGHG1, immunologlulin mu heavy chain and FCN2 protein in the peripheral blood of the patients with different chemotherapy responses are remarkably different (figure 1).
Setting the seed number as 2019, randomly grouping according to the ratio of 2: 1 to construct a training set and a verification set, and importing concentration matrixes of 5 proteins, treatment response conditions and corresponding clinical information: and (3) constructing a model by using a random forest algorithm according to the sex, the age, the tumor marker and the tumor size and position, and repeating the operation for 100 times to obtain an ROC working curve for average prediction of the model. Setting the number of trees as 1000, the minimum observed data number of the peripheral nodes as 1: 5, and fitting by using a anger function to obtain a final model. The decision tree of the extraction model shows that the 5 serum proteins can be used for efficiently predicting the pancreatic cancer of the sample set, and the accuracy is as high as 95%. Based on this decision tree, it could be found that high expression of serum GSN, APOA4, immunolobulin mu heavy chain, FCN2 and low expression of IGHG1 correlated with tumor sensitivity to the FOLFIRINOX regimen (fig. 2).
Example 4
Based on the analysis of the random forest model on the verification queue, the ROC curve shows that the prediction model based on the combination of plasma protein molecules GSN, APOA4, IGHG1, immunolobulin mu heavy chain and FCN2 and the age of the patient can effectively predict the chemotherapy response condition of the pancreatic cancer patient, and the area under the ROC curve can reach 0.915 (figure 3). In particular, sensitivity can reach more than 80% while ensuring 100% diagnostic specificity. The prediction efficiency is significantly better than that of the traditional three-protein marker combination model (fig. 5 and table 1) established based on the binary Logistic regression analysis and in the presence of the single-protein marker model (the result is shown in fig. 4 by using the wilson/brown model). The latter uses a single queue for training and verification, so that the risk of overfitting is high, and the verification effect in the expanded queue is poor. Therefore, the combination of the plasma protein molecule and clinical data has excellent advantages in the prediction of chemotherapy sensitivity of pancreatic cancer patients, which far exceeds the current standard method used in clinic.
TABLE 1
Protein combinations | AUC |
GAI | 0.810 |
GAF | 0.778 |
GAM | 0.890 |
GIF | 0.833 |
GIM | 0.865 |
GFM | 0.888 |
AIF | 0.835 |
AFM | 0.885 |
IFM | 0.903 |
AIM | 0.808 |
Note: g: GSN, A: APOA4, I: IGHG1, M: IgM heavy chain, F: FCN 2.
In conclusion, the invention discovers for the first time that a chemotherapy sensitivity prediction model based on human plasma protein molecules (comprising GSN, APOA4, IGHG1, immunologlulin mu heavy chain and FCN2, any combination of the five proteins and any combination of parts of the five proteins) has a good prediction effect in pancreatic cancer patients, so that the chemotherapy sensitivity prediction model can be used as an important supplement of the existing chemotherapy response prediction strategy, and the efficiency is far superior to that of the existing clinical method.
Claims (5)
1. A plasma protein molecular composition for detecting cancer chemotherapy sensitivity is characterized by consisting of five proteins of human plasma protein GSN, APOA4, IGHG1, immunoglobin mu heavy chain and FCN2,
the type of cancer is a pancreatic cancer,
the chemotherapy regimen is the FOLFIRINOX regimen.
2. The use of the plasma protein molecule composition of claim 1 as a target for detecting cancer chemosensitivity in the preparation of a kit for detecting cancer chemosensitivity,
the type of cancer is a pancreatic cancer,
the chemotherapy regimen is the FOLFIRINOX regimen.
3. The use of claim 2, wherein the kit is used in a method comprising the steps of measuring the concentrations of human plasma proteins GSN, APOA4, IGHG1, immunologlulin muheavy chain and FCN2 in plasma, and inputting the 5 human plasma protein concentration data into a pre-generated random forest model for predictive assessment of the patient's chemotherapeutic response.
4. The application as claimed in claim 3, wherein the pre-generated random forest model is constructed by:
taking concentration data of human plasma proteins GSN, APOA4, IGHG1, Immunoglobulin mu heavy chain and FCN2 in the plasma of patients with known FOLFIRINOX regimen sensitivity and resistance,
setting the seed number as 2019, randomly grouping according to the ratio of 2: 1 to construct a training set and a verification set, and importing concentration matrixes of 5 proteins, treatment response conditions and corresponding clinical information: and (3) constructing a model by using a random forest algorithm, repeating the operation for 100 times to obtain an ROC working curve for average prediction of the model, setting the number of trees to be 1000, setting the minimum observed data number of the peripheral nodes to be 1: 5, and fitting by using a anger function to obtain a final model.
5. A kit for detecting cancer chemotherapy sensitivity, comprising the following reagents:
(1) reagents for extracting proteins from plasma;
(2) a reagent for detecting the concentrations of human plasma proteins GSN, APOA4, IGHG1, immunolobulin muheavy chain and FCN2,
the type of cancer is a pancreatic cancer,
the chemotherapy regimen is the FOLFIRINOX regimen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910924077.0A CN110780070B (en) | 2019-09-27 | 2019-09-27 | Plasma protein molecule for detecting cancer chemotherapy sensitivity, application and kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910924077.0A CN110780070B (en) | 2019-09-27 | 2019-09-27 | Plasma protein molecule for detecting cancer chemotherapy sensitivity, application and kit |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110780070A CN110780070A (en) | 2020-02-11 |
CN110780070B true CN110780070B (en) | 2021-07-06 |
Family
ID=69384789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910924077.0A Active CN110780070B (en) | 2019-09-27 | 2019-09-27 | Plasma protein molecule for detecting cancer chemotherapy sensitivity, application and kit |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110780070B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113917149B (en) * | 2021-09-30 | 2024-05-24 | 江苏扬新生物医药有限公司 | Application of gelsolin detector in preparation of uterine cancer assessment detection reagent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016145128A1 (en) * | 2015-03-09 | 2016-09-15 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
-
2019
- 2019-09-27 CN CN201910924077.0A patent/CN110780070B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016145128A1 (en) * | 2015-03-09 | 2016-09-15 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
Non-Patent Citations (3)
Title |
---|
Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients;Fleur van der Sijde,et al,;《Cancers》;20190115;第11卷(第93期);摘要,第2页最后1段至第3页第1段,第4页最后1段至第5页最后1段 * |
Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy;Hong Peng,et al;《Clin Proteom》;20190717;第16卷;摘要,图5-6,表2 * |
乳腺癌患者血清GSN与ORM1差异表达与化疗耐药相关性初步研究;矫爱红 等;《中华肿瘤防治杂志》;20140630;第21卷(第12期);摘要、第924页左栏第3段 * |
Also Published As
Publication number | Publication date |
---|---|
CN110780070A (en) | 2020-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110577998A (en) | Construction of molecular model for predicting postoperative early recurrence risk of liver cancer and application evaluation thereof | |
JP2020510816A (en) | Methods for detection and treatment of lung cancer | |
Srinivasan et al. | Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis | |
JP2013532830A (en) | Biomarker for prostate cancer and method of using the same | |
EP2362942A1 (en) | Biomarkers | |
US20180100858A1 (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
CN112331343A (en) | Method for establishing hepatocellular carcinoma postoperative risk assessment model | |
CN115798712B (en) | System for diagnosing whether person to be tested is breast cancer or not and biomarker | |
CN111370061A (en) | Cancer screening method based on protein marker and artificial intelligence | |
CN109844534B (en) | Method for prognosis and prediction of breast cancer recurrence, marker used therein and kit thereof | |
CN110780070B (en) | Plasma protein molecule for detecting cancer chemotherapy sensitivity, application and kit | |
CN113584175A (en) | Group of molecular markers for evaluating renal papillary cell carcinoma progression risk and screening method and application thereof | |
CN112961920A (en) | Method and product for predicting curative effect of combination of immune checkpoint inhibitor and targeted therapy of hepatobiliary tumor patient | |
CN112375832A (en) | Intestinal flora combination and screening and model establishing method for representing lung adenocarcinoma qi-yin deficiency syndrome | |
EP4318493A1 (en) | Artificial-intelligence-based method for detecting tumor-derived mutation of cell-free dna, and method for early diagnosis of cancer, using same | |
JP2020533663A (en) | DNA repair profiling and methods for it | |
CN114758719A (en) | Colorectal cancer prediction system and application thereof | |
CN114480636A (en) | Application of bile bacteria as diagnosis and prognosis marker of hepatic portal bile duct cancer | |
CN116735889B (en) | Protein marker for early colorectal cancer screening, kit and application | |
CN115792247B (en) | Application of protein combination in preparation of thyroid papillary carcinoma risk auxiliary layering system | |
EP2730922B1 (en) | Method and system for detecting lymphosarcoma in cats using biomarkers | |
AU2022254718A1 (en) | Method of detecting cancer using genome-wide cfdna fragmentation profiles | |
WO2023073075A1 (en) | Biomarker for immune checkpoint inhibitor sensitive cancer | |
Venancio et al. | Potential of molecular diagnostic methods in the early identification of multiple myeloma: an integrative review | |
Ramdani et al. | P33. 20 Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |